Bristol's Belatacept Gets Wary Green Light From FDA Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The company proposed a REMS in advance for the kidney transplant drug, and post-market safety monitoring is indeed essential, committee members said.
You may also be interested in...
Bristol's Belatacept Could See Approval In Second Quarter After GMP Delay
The kidney transplant drug Nulojix (belatacept) is finished at the plant in Puerto Rico that won't be inspection-ready until the end of the year following a August warning letter.
Bristol's Belatacept Could See Approval In Second Quarter After GMP Delay
The kidney transplant drug Nulojix (belatacept) is finished at the plant in Puerto Rico that won't be inspection-ready until the end of the year following a August warning letter.
When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.